Nearly Half of 49 Legal California Cannabis Products Fail a Pesticide Screen

A fresh round of product screening is raising uncomfortable questions about how well California's regulated cannabis market keeps contaminants off store shelves. A Los Angeles newspaper screened 49 products from the state's legal market, and nearly half turned up something that shouldn't be there. The findings included pesticides that are already banned, along with other toxic ingredients that are scheduled to be outlawed in 2028.

That two-part result matters. Banned pesticides showing up in licensed products suggests that compliance testing, at least in some cases, isn't catching everything. The ingredients slated for prohibition in 2028 point to a different issue: rules that currently allow certain substances but are set to tighten. Products on shelves today may contain compounds regulators have already decided shouldn't be in cannabis down the road.

For consumers, the legal market is supposed to be the safer alternative to unregulated product. Lab testing and state-set limits are a big part of that promise, and people who pay licensed-shop prices reasonably expect that what they're inhaling or ingesting has been checked. Findings like these put that trust under pressure, especially for medical patients and anyone with a compromised immune system who may be more sensitive to contaminants.

For cultivators, manufacturers, and retailers, the report is a reminder that pesticide management is both a regulatory and a reputational risk. Operators who rely on outside suppliers or input products may want to look closely at what goes into their grows and extractions, and at how their testing partners verify results. The 2028 deadline also gives businesses a window to reformulate and adjust sourcing before the restrictions take effect.

The screening covered only 49 products, so it's a snapshot rather than a full audit of California's market. Still, with close to half flagged, it's likely to draw attention from regulators, lab operators, and lawmakers. It also keeps the spotlight on whether testing standards in the nation's largest legal cannabis market are strong enough.